NASDAQ NMS - GLOBAL MARKET · APMD
+3.17% · +$0.8900 · Vol 3.1M
Market closed · last close 4:00 PM ET · price as of 16:15:22 ET
Apnimed Inc

Apnimed Inc

Pharmaceuticals
$29.00
Card
Relationship Map

Follow $APMD

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $APMD by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Earnings absence reason unknown · No analyst covers this company
APMD
Apnimed Inc
Sun Sep 20 · market closed · Markets closed · resumes Mon 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

46/ 100
Veridion Score
Middle range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4 of 6 factors measured · Sun Sep 20 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is APMD moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading APMD catalysts
About Apnimed Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2026
Country
US

Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$28.34
Day high
$30.22
Day low
$27.99
Previous close
$28.11
52W high
$32.55
-10.91% from high
52W low
$24.87
54% of range
Market cap
$1.2B
EPS
$-3.2190
Beta
1.96
Shares out
41.6M
Volume
3.1M
7.05× rel vol
Avg volume
445.7K
VWAP
$28.99
Price history computed in-house
1W
+10.56%
1M
+3.46%
SMA 50 Not reported · Not reported
SMA 200 Not reported · Not reported
52W position 54%

APMD overview

Veridion Score
46
Registered · 2026-09-18
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around APMD.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading APMD Form 4 filings
Public disclosures

Congress activity in APMD

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for APMD in the cached public ledger.

Federal contracts

APMD contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for APMD in this window.
Lobbying spend

APMD lobbying filings, year to date.

Registered lobbying filings matched to Apnimed Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for APMD in this window.
Loading news for APMD
Analyst ratings
Sovereign unlock shows live analyst consensus for APMD.
Options
Sovereign unlock shows live options positioning for APMD.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.